IL291131A - Formulations of anti-il-23p19 antibodies - Google Patents

Formulations of anti-il-23p19 antibodies

Info

Publication number
IL291131A
IL291131A IL291131A IL29113122A IL291131A IL 291131 A IL291131 A IL 291131A IL 291131 A IL291131 A IL 291131A IL 29113122 A IL29113122 A IL 29113122A IL 291131 A IL291131 A IL 291131A
Authority
IL
Israel
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
IL291131A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL291131A publication Critical patent/IL291131A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL291131A 2019-09-09 2022-03-06 Formulations of anti-il-23p19 antibodies IL291131A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962897930P 2019-09-09 2019-09-09
PCT/IB2020/058347 WO2021048743A1 (en) 2019-09-09 2020-09-09 Anti-il-23p19 antibody formulations

Publications (1)

Publication Number Publication Date
IL291131A true IL291131A (en) 2022-05-01

Family

ID=72615913

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291131A IL291131A (en) 2019-09-09 2022-03-06 Formulations of anti-il-23p19 antibodies

Country Status (14)

Country Link
US (1) US12577297B2 (https=)
EP (1) EP4028419A1 (https=)
JP (2) JP2022547162A (https=)
KR (1) KR20220062359A (https=)
CN (1) CN114340674A (https=)
AU (1) AU2020345071A1 (https=)
BR (1) BR112022003169A2 (https=)
CA (1) CA3147328A1 (https=)
CL (1) CL2024002086A1 (https=)
IL (1) IL291131A (https=)
MX (1) MX2022002850A (https=)
PH (1) PH12022550558A1 (https=)
TW (2) TW202123965A (https=)
WO (1) WO2021048743A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
KR20250039516A (ko) * 2022-06-15 2025-03-20 애브비 인코포레이티드 리산키주맙 조성물
CA3263219A1 (en) * 2022-10-21 2024-04-25 Chong Kun Dang Pharmaceutical Corp. STABLE ANTIBODY COMPOSITION
AU2024349247A1 (en) * 2023-09-27 2026-04-16 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-23 antibody
WO2025137347A1 (en) * 2023-12-20 2025-06-26 Abbvie Inc. High concentration risankizumab formulations
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
WO1999054357A1 (en) 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
CA2388562C (en) 1999-09-09 2014-07-22 Schering Corporation Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
CA2408571C (en) 2000-05-10 2014-04-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
EP1449431A4 (en) 2001-10-24 2007-11-28 Chugai Pharmaceutical Co Ltd SGRF-TRANSGENIC NON-MENTAL ANIMAL
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7510709B2 (en) 2002-10-30 2009-03-31 Genentech, Inc. Method of treating inflammatory disease by inhibition of IL-17 production
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
WO2005005612A2 (en) 2003-07-01 2005-01-20 University Of Virginia Patent Foundation Tag-1 and tag-2 proteins and uses thereof
PT1694360E (pt) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544951A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CN1993480A (zh) 2004-05-03 2007-07-04 先灵公司 Il－17表达预测皮肤炎症的用途；治疗方法
US20060084145A1 (en) 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2292758A3 (en) 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
CA2612785A1 (en) 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the il-12 family of cytokines
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
PL1933869T3 (pl) 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
EP1977007A4 (en) 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CA2652924A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
CN101600456A (zh) 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20080200591A1 (en) 2007-02-15 2008-08-21 Isao Noda Melt Processable Reactive Pellets Capable of Forming Ester Condensates and Process for Forming Melt Processable Reactive Pellets
CN101605532A (zh) 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
BRPI0810561A2 (pt) 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
PL2197903T3 (pl) 2007-09-04 2015-03-31 Us Gov Health & Human Services Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2212442A1 (en) 2007-10-26 2010-08-04 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2010062896A1 (en) 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CN102695465A (zh) 2009-12-02 2012-09-26 斯帕泰克医疗股份有限公司 结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
KR20130010461A (ko) 2010-02-18 2013-01-28 브리스톨-마이어스 스큅 컴퍼니 Ｉｌ―２３에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US20110318741A1 (en) 2010-06-15 2011-12-29 Schafer Peter H Biomarkers for the treatment of psoriasis
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
JP6173911B2 (ja) 2010-09-10 2017-08-09 メディミューン リミテド 抗体誘導体
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
WO2014039903A2 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
EP2968488A1 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
EP3283109A1 (en) 2015-04-14 2018-02-21 Boehringer Ingelheim International GmbH Methods of treating diseases
IL256665B2 (en) 2015-07-23 2023-10-01 Boehringer Ingelheim Int IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
SI3386541T1 (sl) 2015-12-07 2020-11-30 Merck Patent Gbmh Vodna farmacevtska formulacija, ki vsebuje protitelo proti PD-1 avelumab
EP3560956A3 (en) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
SG11201901081XA (en) 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
EP3526252A2 (en) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Methods of treating diseases with il-23a antibody
EP3810268A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
CA3263219A1 (en) 2022-10-21 2024-04-25 Chong Kun Dang Pharmaceutical Corp. STABLE ANTIBODY COMPOSITION

Also Published As

Publication number Publication date
JP2025163108A (ja) 2025-10-28
TW202535466A (zh) 2025-09-16
CL2024002086A1 (es) 2025-01-10
AU2020345071A1 (en) 2022-03-24
KR20220062359A (ko) 2022-05-16
US12577297B2 (en) 2026-03-17
MX2022002850A (es) 2022-04-06
US20210070852A1 (en) 2021-03-11
JP2022547162A (ja) 2022-11-10
BR112022003169A2 (pt) 2022-05-17
WO2021048743A1 (en) 2021-03-18
CN114340674A (zh) 2022-04-12
CA3147328A1 (en) 2021-03-18
TW202123965A (zh) 2021-07-01
PH12022550558A1 (en) 2023-02-20
EP4028419A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL286100A (en) Formulations of anti-il-36r antibodies
IL291131A (en) Formulations of anti-il-23p19 antibodies
ZA202006263B (en) Antibody formulation
GB201905150D0 (en) Ant-ige antibodies
IL276626A (en) Formulations of B7-H4 antibody
SG11202103064YA (en) Antibody formulation
ZA202108836B (en) Anti-epha4 antibody
SG11202102875YA (en) Anti-fgfr2 antibody formulations
IL284584A (en) Anti-tigit antibodies
SG11202104300PA (en) Antibody formulation
SG11202104012QA (en) Antibody formulations
GB201809976D0 (en) Novel formulations
GB201905477D0 (en) Novel formulations
IL290356A (en) Formulations for Resotide
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) formulations
GB201900732D0 (en) Antibodies
GB201919062D0 (en) Antibody
GB201917480D0 (en) Antibodies
SG11201913540VA (en) Anti-Podoplanin Antibody
SG11202009872YA (en) Stable antibody formulation
IL310275A (en) Antibody formulations
IL289160A (en) Anti-angpt2 antibodies